The significance of TP53 in lymphoid malignancies: Mutation prevalence, regulation, prognostic impact and potential as a therapeutic target

British Journal of Haematology

Volumn 146, Issue 3, 2009, Pages 257-269

  Cheung, K John J ^a   Horsman, Douglas E ^a   Gascoyne, Randy D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Acute myeloid leukaemia; ALL; Lymphomas; Paediatric haematology

Indexed keywords

PROTEIN P53;

GENE DELETION; GENE FUNCTION; GENE MUTATION; GENOMIC INSTABILITY; HEMATOLOGIC MALIGNANCY; LYMPHOMA; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; LYMPHOMA; MUTATION; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67650472752     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07739.x     Document Type: Review

References (115)

1. Agarwal, N. Gewirtz, A.M. (1999) Oligonucleotide therapeutics for haematologic disorders. Biochimica Et Biophysica Acta, 1489, 85 96.
2. Ashkenazi, A. (2008) Targeting the extrinsic apoptosis pathway in cancer. Cytokine & Growth Factor Reviews, 19, 325 331.
3. Ashkenazi, A., Pai, R.C., Fong, S., Leung, S., Lawrence, D.A., Marsters, S.A., Blackie, C., Chang, L., McMurtrey, A.E., Hebert, A., DeForge, L., Koumenis, I.L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z. Schwall, R.H. (1999) Safety and antitumour activity of recombinant soluble Apo2 ligand. The Journal of Clinical Investigation, 104, 155 162.
4. Austen, B., Skowronska, A., Baker, C., Powell, J.E., Gardiner, A., Oscier, D., Majid, A., Dyer, M., Siebert, R., Taylor, A.M., Moss, P.A. Stankovic, T. (2007) Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. Journal of Clinical Oncology, 25, 5448 5457. (Pubitemid 350232222)
5. Baldini, L., Fracchiolla, N.S., Cro, L.M., Trecca, D., Romitti, L., Polli, E., Maiolo, A.T. Neri, A. (1994) Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin. Blood, 84, 270 278. (Pubitemid 24193830)
6. Barnabas, N., Shurafa, M., Van Dyke, D.L., Wolman, S.R., Clark, D. Worsham, M.J. (2001) Significance of p53 mutations in patients with chronic lymphocytic leukemia: a sequential study of 30 patients. Cancer, 91, 285 293. (Pubitemid 32099228)
7. Bassett, E.A., Wang, W., Rastinejad, F. El-Deiry, W.S. (2008) Structural and functional basis for therapeutic modulation of p53 signaling. Clinical Cancer Research, 14, 6376 6386.
8. Bhatia, K.G., Gutierrez, M.I., Huppi, K., Siwarski, D. Magrath, I.T. (1992) The pattern of p53 mutations in burkitt's lymphoma differs from that of solid tumours. Cancer Research, 52, 4273 4276.
9. Bishop, M.R., Iversen, P.L., Bayever, E., Sharp, J.G., Greiner, T.C., Copple, B.L., Ruddon, R., Zon, G., Spinolo, J., Arneson, M., Armitage, J.O. Kessinger, A. (1996) Phase I trial of an antisense oligonucleotide OL(1)p53 in haematologic malignancies. Journal of Clinical Oncology, 14, 1320 1326. (Pubitemid 26105542)
10. Bourdon, J.C. (2007) P53 and its isoforms in cancer. British Journal of Cancer, 97, 277 282.
11. Brink, A.A., Oudejans, J.J., van den Brule, A.J., Kluin, P.M., Horstman, A., Ossenkoppele, G.J., van Heerde, P., Jiwa, M. Meijer, C.J. (1998) Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for hodgkin's disease: involvement of apoptosis resistance? Modern Pathology, 11, 376 383. (Pubitemid 28208101)
12. Bueso-Ramos, C.E., Yang, Y., deLeon, E., McCown, P., Stass, S.A. Albitar, M. (1993) The human MDM-2 oncogene is overexpressed in leukemias. Blood, 82, 2617 2623. (Pubitemid 23318067)
13. Bullrich, F., Rasio, D., Kitada, S., Starostik, P., Kipps, T., Keating, M., Albitar, M., Reed, J.C. Croce, C.M. (1999) ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Research, 59, 24 27. (Pubitemid 29062949)
14. Bykov, V.J., Issaeva, N., Selivanova, G. Wiman, K.G. (2002) Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the national cancer institute database. Carcinogenesis, 23, 2011 2018. (Pubitemid 36104953)
15. Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M.J., Bezares, R.F., Pettitt, A.R., Hamblin, T., Milligan, D.W., Child, J.A., Hamilton, M.S., Dearden, C.E., Smith, A.G., Bosanquet, A.G., Davis, Z., Brito-Babapulle, V., Else, M., Wade, R., Hillmen, P. UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group, N C R I Chronic Lymphocytic Leukaemia Working Group 2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet, 370, 230 239. (Pubitemid 47069536)
16. Cesarman, E., Chadburn, A., Inghirami, G., Gaidano, G. Knowles, D.M. (1992) Structural and functional analysis of oncogenes and tumour suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood, 80, 3205 3216. (Pubitemid 23004526)
17. Cesarman, E., Inghirami, G., Chadburn, A. Knowles, D.M. (1993) High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. The American Journal of Pathology, 143, 845 856. (Pubitemid 24058240)
18. Chilosi, M., Doglioni, C., Menestrina, F., Montagna, L., Rigo, A., Lestani, M., Barbareschi, M., Scarpa, A., Mariuzzi, G.M. Pizzolo, G. (1994) Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood, 84, 4295 4300. (Pubitemid 24371935)
19. Cobo, F., Martinez, A., Pinyol, M., Hernandez, L., Gomez, M., Bea, S., Esteve, J., Rozman, M., Bosch, F., Lopez-Guillermo, A., Montserrat, E. Campo, E. (2002) Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia. Leukemia, 16, 1028 1034. (Pubitemid 34618841)
20. Coll-Mulet, L., Iglesias-Serret, D., Santidrian, A.F., Cosialls, A.M., de Frias, M., Castano, E., Campas, C., Barragan, M., de Sevilla, A.F., Domingo, A., Vassilev, L.T., Pons, G. Gil, J. (2006) MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood, 107, 4109 4114. (Pubitemid 43726820)
21. Cotter, F.E. (1999) Antisense therapy of haematologic malignancies. Seminars in Hematology, 36, 9 14.
22. De Angeli, C., Gandini, D., Cuneo, A., Moretti, S., Bigoni, R., Roberti, M.G., Bardi, A., Castoldi, G.L. del Senno, L. (2000) BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;q32). Haematologica, 85, 913 921. (Pubitemid 30769836)
23. Dicker, F., Herholz, H., Schnittger, S., Nakao, A., Patten, N., Wu, L., Kern, W., Haferlach, T. Haferlach, C. (2009) The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia, 23, 117 124.
24. Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J. Stilgenbauer, S. (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood, 85, 1580 1589.
25. Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M. Lichter, P. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. The New England Journal of Medicine, 343, 1910 1916. (Pubitemid 32064784)
26. Drakos, E., Thomaides, A., Medeiros, L.J., Li, J., Leventaki, V., Konopleva, M., Andreeff, M. Rassidakis, G.Z. (2007) Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clinical Cancer Research, 13, 3380 3387. (Pubitemid 46944926)
27. Du, M., Peng, H., Singh, N., Isaacson, P.G. Pan, L. (1995) The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood, 86, 4587 4593.
28. Elenitoba-Johnson, K.S., Medeiros, L.J., Khorsand, J. King, T.C. (1996) P53 expression in Reed-Sternberg cells does not correlate with gene mutations in Hodgkin's disease. American Journal of Clinical Pathology, 106, 728 738.
29. Fenaux, P., Preudhomme, C., Lai, J.L., Quiquandon, I., Jonveaux, P., Vanrumbeke, M., Sartiaux, C., Morel, P., Loucheux-Lefebvre, M.H. Bauters, F. (1992) Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia, 6, 246 250.
30. Gaidano, G., Ballerini, P., Gong, J.Z., Inghirami, G., Neri, A., Newcomb, E.W., Magrath, I.T., Knowles, D.M. Dalla-Favera, R. (1991) p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 88, 5413 5417. (Pubitemid 21914755)
31. Greiner, T.C., Moynihan, M.J., Chan, W.C., Lytle, D.M., Pedersen, A., Anderson, J.R. Weisenburger, D.D. (1996) P53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood, 87, 4302 4310. (Pubitemid 26152272)
32. Grever, M.R., Lucas, D.M., Dewald, G.W., Neuberg, D.S., Reed, J.C., Kitada, S., Flinn, I.W., Tallman, M.S., Appelbaum, F.R., Larson, R.A., Paietta, E., Jelinek, D.F., Gribben, J.G. Byrd, J.C. (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US intergroup phase III trial E2997. Journal of Clinical Oncology, 25, 799 804. (Pubitemid 350010635)
33. Hainaut, P., Hernandez, T., Robinson, A., Rodriguez-Tome, P., Flores, T., Hollstein, M., Harris, C.C. Montesano, R. (1998) IARC database of p53 gene mutations in human tumours and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Research, 26, 205 213. (Pubitemid 28291534)
34. Hartmann, E., Fernandez, V., Stoecklein, H., Hernandez, L., Campo, E. Rosenwald, A. (2007) Increased MDM2 expression is associated with inferior survival in mantle-cell lymphoma, but not related to the MDM2 SNP309. Haematologica, 92, 574 575. (Pubitemid 350144311)
35. Hawkins, J.M., Moorman, A.V., Hoffbrand, A.V., Martineau, M., Wright, F.S., Mehta, A.B., Prentice, H.G. Secker-Walker, L.M. (1994) Association of 17p loss with late-stage or refractory disease in haematologic malignancy. Cancer Genetics and Cytogenetics, 77, 134 143. (Pubitemid 24346077)
36. Henson, E.S., Johnston, J.B. Gibson, S.B. (2008) The role of TRAIL death receptors in the treatment of hematological malignancies. Leukemia & Lymphoma, 49, 27 35. (Pubitemid 351146879)
37. Hernandez, L., Fest, T., Cazorla, M., Teruya-Feldstein, J., Bosch, F., Peinado, M.A., Piris, M.A., Montserrat, E., Cardesa, A., Jaffe, E.S., Campo, E. Raffeld, M. (1996) P53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood, 87, 3351 3359. (Pubitemid 26115366)
38. Hernandez, L., Bea, S., Pinyol, M., Ott, G., Katzenberger, T., Rosenwald, A., Bosch, F., Lopez-Guillermo, A., Delabie, J., Colomer, D., Montserrat, E. Campo, E. (2005) CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Research, 65, 2199 2206. (Pubitemid 40490128)
39. Hollstein, M., Sidransky, D., Vogelstein, B. Harris, C.C. (1991) P53 mutations in human cancers. Science (New York, NY), 253, 49 53. (Pubitemid 21917115)
40. Ichikawa, A., Hotta, T., Takagi, N., Tsushita, K., Kinoshita, T., Nagai, H., Murakami, Y., Hayashi, K. Saito, H. (1992) Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood, 79, 2701 2707.
41. Ichikawa, A., Kinoshita, T., Watanabe, T., Kato, H., Nagai, H., Tsushita, K., Saito, H. Hotta, T. (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. The New England Journal of Medicine, 337, 529 534. (Pubitemid 27352019)
42. Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L.G., Masucci, M., Pramanik, A. Selivanova, G. (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumours. Nature Medicine, 10, 1321 1328. (Pubitemid 40022713)
43. Janz, M., Stuhmer, T., Vassilev, L.T. Bargou, R.C. (2007) Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells. Leukemia, 21, 772 779. (Pubitemid 46444562)
44. Kaneko, H., Sugita, K., Kiyokawa, N., Iizuka, K., Takada, K., Saito, M., Yoshimoto, K., Itakura, M., Kokai, Y. Fujimoto, J. (1996) Lack of CD54 expression and mutation of p53 gene relate to the prognosis of childhood Burkitt's lymphoma. Leukemia & Lymphoma, 21, 449 455. (Pubitemid 26141227)
45. Kastan, M.B. Berkovich, E. (2007) P53: a two-faced cancer gene. Nature Cell Biology, 9, 489 491.
46. Kawamata, N., Miller, C., Levy, V., Shintaku, I.P., Koeffler, H.P. Said, J.W. (1996) Mdm-2 oncogene expression in non-Hodgkin's lymphomas. Diagnostic Molecular Pathology: The American Journal of Surgical Pathology, Part B, 5, 33 38. (Pubitemid 26069557)
47. Kim, E. Deppert, W. (2004) Transcriptional activities of mutant p53: when mutations are more than a loss. Journal of Cellular Biochemistry, 93, 878 886. (Pubitemid 44264143)
48. Kojima, K., Konopleva, M., McQueen, T., O'Brien, S., Plunkett, W. Andreeff, M. (2006) Mdm2 inhibitor nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood, 108, 993 1000. (Pubitemid 44154636)
49. Konig, E.A., Kusser, W.C., Day, C., Porzsolt, F., Glickman, B.W., Messer, G., Schmid, M., de Chatel, R., Marcsek, Z.L. Demeter, J. (2000) P53 mutations in hairy cell leukemia. Leukemia, 14, 706 711. (Pubitemid 30195463)
50. Kramer, M.H., Hermans, J., Parker, J., Krol, A.D., Kluin-Nelemans, J.C., Haak, H.L., van Groningen, K., van Krieken, J.H., de Jong, D. Kluin, P.M. (1996) Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. Journal of Clinical Oncology, 14, 2131 2138. (Pubitemid 26230116)
51. Krug, U., Ganser, A. Koeffler, H.P. (2002) Tumour suppressor genes in normal and malignant hematopoiesis. Oncogene, 21, 3475 3495. (Pubitemid 34587717)
52. Kupper, M., Joos, S., von Bonin, F., Daus, H., Pfreundschuh, M., Lichter, P. Trumper, L. (2001) MDM2 gene amplification and lack of p53 point mutations in hodgkin and reed-sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. British Journal of Haematology, 112, 768 775. (Pubitemid 32222851)
53. Lai, R., Medeiros, L.J., Wilson, C.S., Sun, N.C., Koo, C., McCourty, A. Brynes, R.K. (1998) Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity. Modern Pathology, 11, 642 647. (Pubitemid 28335142)
54. Lane, D.P. Crawford, L.V. (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature, 278, 261 263. (Pubitemid 9129076)
55. Lazaridou, A., Miraxtsi, C., Korantzis, J., Eleftheriadis, N. Christakis, J.I. (2000) Simultaneous detection of BCL-2 protein, trisomy 12, retinoblastoma and P53 monoallelic gene deletions in B-cell chronic lymphocytic leukemia by fluorescence in situ hybridization (FISH): relation to disease status. Leukemia & Lymphoma, 36, 503 512. (Pubitemid 30103175)
56. Leroy, K., Haioun, C., Lepage, E., Le Metayer, N., Berger, F., Labouyrie, E., Meignin, V., Petit, B., Bastard, C., Salles, G., Gisselbrecht, C., Reyes, F., Gaulard, P. Groupe d'Etude des Lymphomes de l'Adulte. (2002) p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Annals of Oncology, 13, 1108 1115. (Pubitemid 34885013)
57. Levine, A.J., Hu, W. Feng, Z. (2006) The P53 pathway: what questions remain to be explored? Cell Death and Differentiation, 13, 1027 1036. (Pubitemid 43753493)
58. Lo Coco, F., Gaidano, G., Louie, D.C., Offit, K., Chaganti, R.S. Dalla-Favera, R. (1993) P53 mutations are associated with histologic transformation of follicular lymphoma. Blood, 82, 2289 2295. (Pubitemid 23304250)
59. Maggio, E.M., Stekelenburg, E., Van den Berg, A. Poppema, S. (2001) TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus. International Journal of Cancer, 94, 60 66. (Pubitemid 32801753)
60. Malkin, D. (2001) The role of p53 in human cancer. Journal of Neuro-Oncology, 51, 231 243. (Pubitemid 32479297)
61. Meeker, T.C., Lay, L.T., Wroblewski, J.M., Turturro, F., Li, Z. Seth, P. (1997) Adenoviral vectors efficiently target cell lines derived from selected lymphocytic malignancies, including anaplastic large cell lymphoma and Hodgkin's disease. Clinical Cancer Research, 3, 357 364. (Pubitemid 27158058)
62. Moller, M.B., Ino, Y., Gerdes, A.M., Skjodt, K., Louis, D.N. Pedersen, N.T. (1999) Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia, 13, 453 459. (Pubitemid 29108084)
63. Momand, J., Zambetti, G.P., Olson, D.C., George, D. Levine, A.J. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237 1245.
64. Montalban, C., Garcia, J.F., Abraira, V., Gonzalez-Camacho, L., Morente, M.M., Bello, J.L., Conde, E., Cruz, M.A., Garcia-Sanz, R., Garcia-Larana, J., Grande, C., Llanos, M., Martinez, R., Flores, E., Mendez, M., Ponderos, C., Rayon, C., Sanchez-Godoy, P., Zamora, J., Piris, M.A. Spanish Hodgkin's Lymphoma Study Group. (2004) Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the spanish Hodgkin's lymphoma study group. Journal of Clinical Oncology, 22, 1664 1673. (Pubitemid 41079805)
65. Montesinos-Rongen, M., Roers, A., Kuppers, R., Rajewsky, K. Hansmann, M.L. (1999) Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood, 94, 1755 1760. (Pubitemid 29411326)
66. Nahi, H., Selivanova, G., Lehmann, S., Mollgard, L., Bengtzen, S., Concha, H., Svensson, A., Wiman, K.G., Merup, M. Paul, C. (2008) Mutated and non-mutated TP53 as targets in the treatment of leukaemia. British Journal of Haematology, 141, 445 453. (Pubitemid 351550548)
67. Newcomb, E.W. (1995) P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leukemia & Lymphoma, 17, 211 221.
68. O'Shea, D., O'Riain, C., Taylor, C., Waters, R., Carlotti, E., Macdougall, F., Gribben, J., Rosenwald, A., Ott, G., Rimsza, L.M., Smeland, E.B., Johnson, N., Campo, E., Greiner, T.C., Chan, W.C., Gascoyne, R.D., Wright, G., Staudt, L.M., Lister, T.A. Fitzgibbon, J. (2008) The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and a poorer overall survival. Blood, 112, 3126 3129.
69. Peart, M.J. Prives, C. (2006) Mutant p53 gain of function: the NF-Y connection. Cancer Cell, 10, 173 174. (Pubitemid 44311071)
70. Peller, S. Rotter, V. (2003) TP53 in haematological cancer: low incidence of mutations with significant clinical relevance. Human Mutation, 21, 277 284. (Pubitemid 36292969)
71. Pennanen, H., Kuittinen, O., Soini, Y. Turpeenniemi-Hujanen, T. (2008) Prognostic significance of p53 and MMP-9 expression in follicular lymphoma. European Journal of Haematology, 81, 289 297.
72. Pescarmona, E., Pignoloni, P., Santangelo, C., Naso, G., Realacci, M., Cela, O., Lavinia, A.M., Martelli, M., Russo, M.A. Baroni, C.D. (1999) Expression of p53 and retinoblastoma gene in high-grade nodal peripheral T-cell lymphomas: immunohistochemical and molecular findings suggesting different pathogenetic pathways and possible clinical implications. The Journal of Pathology, 188, 400 406. (Pubitemid 29327439)
73. Pettitt, A.R., Sherrington, P.D., Stewart, G., Cawley, J.C., Taylor, A.M. Stankovic, T. (2001) p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood, 98, 814 822.
74. Piris, M.A., Pezzella, F., Martinez-Montero, J.C., Orradre, J.L., Villuendas, R., Sanchez-Beato, M., Cuena, R., Cruz, M.A., Martinez, B. Pezella, F. corrected to Pezzella 1994) p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. British Journal of Cancer, 69, 337 341. (Pubitemid 24046559)
75. Preudhomme, C. Fenaux, P. (1997) The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies. British Journal of Haematology, 98, 502 511. (Pubitemid 27386527)
76. Preudhomme, C., Dervite, I., Wattel, E., Vanrumbeke, M., Flactif, M., Lai, J.L., Hecquet, B., Coppin, M.C., Nelken, B. Gosselin, B. (1995) Clinical significance of p53 mutations in newly diagnosed burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases. Journal of Clinical Oncology, 13, 812 820.
77. Prokocimer, M., Unger, R., Rennert, H.S., Rotter, V. Rennert, G. (1998) Pooled analysis of p53 mutations in haematological malignancies. Human Mutation, 12, 4 18. (Pubitemid 28262219)
78. Quesnel, B., Preudhomme, C., Oscier, D., Lepelley, P., Collyn-d'Hooghe, M., Facon, T., Zandecki, M. Fenaux, P. (1994) Over-expression of the MDM2 gene is found in some cases of haematological malignancies. British Journal of Haematology, 88, 415 418.
79. Rossi, D., Cerri, M., Deambrogi, C., Sozzi, E., Cresta, S., Rasi, S., De Paoli, L., Spina, V., Gattei, V., Capello, D., Forconi, F., Lauria, F. Gaidano, G. (2009) The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clinical Cancer Research, 15, 995 1004.
80. el Rouby, S., Thomas, A., Costin, D., Rosenberg, C.R., Potmesil, M., Silber, R. Newcomb, E.W. (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood, 82, 3452 3459. (Pubitemid 23356719)
81. Rudenko, H.C., Else, M., Dearden, C., Brito-Babapulle, V., Jones, C., Dexter, T., Fenwick, K., Mackay, A., Ashworth, A., Matutes, E., Gonzalez, D., Catovsky, D. Morgan, G.J. (2008) Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation. Leukemia & Lymphoma, 49, 1879 1886.
82. Sakashita, A., Hattori, T., Miller, C.W., Suzushima, H., Asou, N., Takatsuki, K. Koeffler, H.P. (1992) Mutations of the p53 gene in adult T-cell leukemia. Blood, 79, 477 480.
83. Sander, C.A., Yano, T., Clark, H.M., Harris, C., Longo, D.L., Jaffe, E.S. Raffeld, M. (1993) P53 mutation is associated with progression in follicular lymphomas. Blood, 82, 1994 2004. (Pubitemid 23293979)
84. Schaffner, C., Stilgenbauer, S., Rappold, G.A., Dohner, H. Lichter, P. (1999) Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood, 94, 748 753. (Pubitemid 29323889)
85. Schaffner, C., Idler, I., Stilgenbauer, S., Dohner, H. Lichter, P. (2000) Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proceedings of the National Academy of Sciences of the United States of America, 97, 2773 2778. (Pubitemid 30159247)
86. Secchiero, P., Barbarotto, E., Tiribelli, M., Zerbinati, C., di Iasio, M.G., Gonelli, A., Cavazzini, F., Campioni, D., Fanin, R., Cuneo, A. Zauli, G. (2006) Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood, 107, 4122 4129. (Pubitemid 43726822)
87. Shiloh, Y. (2003) ATM and related protein kinases: safeguarding genome integrity. Nature Reviews Cancer, 3, 155 168. (Pubitemid 37328868)
88. Smolewski, P., Robak, T., Krykowski, E., Blasinska-Morawiec, M., Niewiadomska, H., Pluzanska, A., Chmielowska, E. Zambrano, O. (2000) Prognostic factors in hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clinical Cancer Research, 6, 1150 1160. (Pubitemid 30159379)
89. Sohn, S.K., Jung, J.T., Kim, D.H., Kim, J.G., Kwak, E.K., Park, T., Shin, D.G., Sohn, K.R. Lee, K.B. (2003) Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. American Journal of Hematology, 73, 101 107. (Pubitemid 36578431)
90. Starostik, P., Manshouri, T., O'Brien, S., Freireich, E., Kantarjian, H., Haidar, M., Lerner, S., Keating, M. Albitar, M. (1998) Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Research, 58, 4552 4557. (Pubitemid 28480612)
91. Steele, A.J., Prentice, A.G., Hoffbrand, A.V., Yogashangary, B.C., Hart, S.M., Nacheva, E.P., Howard-Reeves, J.D., Duke, V.M., Kottaridis, P.D., Cwynarski, K., Vassilev, L.T. Wickremasinghe, R.G. (2008) p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood, 112, 3827 3834.
92. Stilgenbauer, S., Winkler, D., Ott, G., Schaffner, C., Leupolt, E., Bentz, M., Moller, P., Muller-Hermelink, H.K., James, M.R., Lichter, P. Dohner, H. (1999) Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. Blood, 94, 3262 3264. (Pubitemid 29512737)
93. Stilgenbauer, S., Bullinger, L., Lichter, P., Dohner, H., German CLL Study Group (GCLLSG), Chronic lymphocytic leukemia. (2002) Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia, 16, 993 1007. (Pubitemid 34618838)
94. Stokke, T., Galteland, E., Holte, H., Smedshammer, L., Suo, Z., Smeland, E.B., Borresen-Dale, A.L., DeAngelis, P. Steen, H.B. (2000) Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell non-Hodgkin's lymphoma. International Journal of Cancer, 89, 313 324. (Pubitemid 30620283)
95. Sturm, I., Bosanquet, A.G., Hermann, S., Guner, D., Dorken, B. Daniel, P.T. (2003) Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death and Differentiation, 10, 477 484. (Pubitemid 36626360)
96. Symmans, W.F., Katz, R.L., Ordonez, N.G., Dalton, H., Romaguera, J.E. Cabanillas, F. (1995) Transformation of follicular lymphoma. expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation. Acta Cytologica, 39, 673 682.
97. Tai, Y.C., Tan, J.A. Peh, S.C. (2004) Higher frequency of p53 gene mutations in diffuse large B-cell lymphoma with MALT component. Pathology International, 54, 811 818.
98. Taylor, A.M., Metcalfe, J.A., Thick, J. Mak, Y.F. (1996) Leukemia and lymphoma in ataxia telangiectasia. Blood, 87, 423 438. (Pubitemid 26030297)
99. Trumper, L.H., Brady, G., Bagg, A., Gray, D., Loke, S.L., Griesser, H., Wagman, R., Braziel, R., Gascoyne, R.D. Vicini, S. (1993) Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations. Blood, 81, 3097 3115. (Pubitemid 23162131)
100. Turturro, F., Heineke, H.L., Drevyanko, T.F., Link, Jr., C.J. Seth, P. (2000a) Adenovirus-p53-mediated gene therapy of anaplastic large cell lymphoma with t(2;5) in a nude mouse model. Gene Therapy, 7, 930 933. (Pubitemid 30386657)
101. Turturro, F., Seth, P. Link, Jr., C.J. (2000b) In vitro adenoviral vector p53-mediated transduction and killing correlates with expression of coxsackie-adenovirus receptor and alpha(nu)beta5 integrin in SUDHL-1 cells derived from anaplastic large-cell lymphoma. Clinical Cancer Research, 6, 185 192. (Pubitemid 30064993)
102. Valganon, M., Giraldo, P., Agirre, X., Larrayoz, M.J., Rubio-Martinez, A., Rubio-Felix, D., Calasanz, M.J. Odero, M.D. (2005) p53 aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages rai III/IV. British Journal of Haematology, 129, 53 59. (Pubitemid 40524051)
103. Vallianatou, K., Brito-Babapulle, V., Matutes, E., Atkinson, S. Catovsky, D. (1999) P53 gene deletion and trisomy 12 in hairy cell leukemia and its variant. Leukemia Research, 23, 1041 1045. (Pubitemid 29488651)
104. Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N. Liu, E.A. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (New York, NY), 303, 844 848. (Pubitemid 38174664)
105. Wang, P., Lushnikova, T., Odvody, J., Greiner, T.C., Jones, S.N. Eischen, C.M. (2008) Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene, 27, 1590 1598. (Pubitemid 351347872)
106. Watanabe, T., Hotta, T., Ichikawa, A., Kinoshita, T., Nagai, H., Uchida, T., Murate, T. Saito, H. (1994) The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood, 84, 3158 3165.
107. Whibley, C., Pharoah, P.D. Hollstein, M. (2009) P53 polymorphisms: cancer implications. Nature Reviews Cancer, 9, 95 107.
108. Wissink, E.H., Verbrugge, I., Vink, S.R., Schader, M.B., Schaefer, U., Walczak, H., Borst, J. Verheij, M. (2006) TRAIL enhances efficacy of radiotherapy in a p53 mutant, bcl-2 overexpressing lymphoid malignancy. Radiotherapy and Oncology, 80, 214 222. (Pubitemid 44301543)
109. Xerri, L., Bouabdallah, R., Camerlo, J. Hassoun, J. (1994) Expression of the p53 gene in Hodgkin's disease: dissociation between immunohistochemistry and clinicopathological data. Human Pathology, 25, 449 454. (Pubitemid 24173861)
110. Xerri, L., Parc, P., Bouabdallah, R., Camerlo, J. Hassoun, J. (1995) PCR-mismatch analysis of p53 gene mutation in Hodgkin's disease. The Journal of Pathology, 175, 189 194.
111. Xu, Y. (2008) Induction of genetic instability by gain-of-function p53 cancer mutants. Oncogene, 27, 3501 3507. (Pubitemid 351793802)
112. Young, K.H., Weisenburger, D.D., Dave, B.J., Smith, L., Sanger, W., Iqbal, J., Campo, E., Delabie, J., Gascoyne, R.D., Ott, G., Rimsza, L., Muller-Hermelink, H.K., Jaffe, E.S., Rosenwald, A., Staudt, L.M., Chan, W.C. Greiner, T.C. (2007) Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood, 110, 4396 4405.
113. Young, K.H., Leroy, K., Moller, M.B., Colleoni, G.W., Sanchez-Beato, M., Kerbauy, F.R., Haioun, C., Eickhoff, J.C., Young, A.H., Gaulard, P., Piris, M.A., Oberley, T.D., Rehrauer, W.M., Kahl, B.S., Malter, J.S., Campo, E., Delabie, J., Gascoyne, R.D., Rosenwald, A., Rimsza, L., Huang, J., Braziel, R.M., Jaffe, E.S., Wilson, W.H., Staudt, L.M., Vose, J.M., Chan, W.C., Weisenburger, D.D. Greiner, T.C. (2008) Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood, 112, 3088 3098.
114. Zainuddin, N., Berglund, M., Wanders, A., Ren, Z.P., Amini, R.M., Lindell, M., Kanduri, M., Roos, G., Rosenquist, R. Enblad, G. (2009) TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. Leukemia Research, 33, 60 66.
115. Zenz, T., Krober, A., Scherer, K., Habe, S., Buhler, A., Benner, A., Denzel, T., Winkler, D., Edelmann, J., Schwanen, C., Dohner, H. Stilgenbauer, S. (2008) Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic: results from a detailed genetic characterization with long-term follow-up. Blood, 112, 3322 3329.